Français
ItalianoBond Bristol Myers Squibb 3.4% ( US110122CB21 ) in USD
| Issuer | Bristol Myers Squibb | ||||||
| Market price |  94.446 % ▼ |
||||||
| Country |  United States
|
||||||
| ISIN code |
 US110122CB21 ( in USD )
|
||||||
| Interest rate | 3.4% per year ( payment 2 times a year) | ||||||
| Maturity | 07/26/2029 | ||||||
| Minimal amount | 2 000 USD | ||||||
| Total amount | 4 000 000 000 USD | ||||||
| Cusip | 110122CB2 | ||||||
| Standard & Poor's ( S&P ) rating | A ( Upper medium grade - Investment-grade ) | ||||||
| Moody's rating | A2 ( Upper medium grade - Investment-grade ) | ||||||
| Next Coupon | 01/26/2027 ( In 92 days ) | ||||||
| Detailed description |
Bristol Myers Squibb is a global biopharmaceutical company engaged in the research, development, and marketing of innovative medicines and biotherapeutics across various therapeutic areas, including oncology, cardiovascular disease, immunology, and fibrosis. The Bond issued by Bristol Myers Squibb ( United States ) , in USD, with the ISIN code US110122CB21, pays a coupon of 3.4% per year. The coupons are paid 2 times per year and the Bond maturity is 07/26/2029 The Bond issued by Bristol Myers Squibb ( United States ) , in USD, with the ISIN code US110122CB21, was rated A2 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency. The Bond issued by Bristol Myers Squibb ( United States ) , in USD, with the ISIN code US110122CB21, was rated A ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
||||||
| |||||||